pharma · Waldenstrom Macroglobulinemia · Non Small Cell Lung Cancer · CLRB
Cellectar Biosciences
Cellectar Biosciences clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 100 Campus Dr, 207, Florham Park, New Jersey 07932, US
- Employees
- 21
- Programs
- 17
- Drugs
- 7
- Patents
- 7
Cellectar Biosciences projects
8 ClinicalTrials.gov programs sponsored by Cellectar Biosciences.
Cellectar Biosciences has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CLR 131
Cellectar Biosciences
Head and Neck Cancer
1 trial -
CLR 131
Cellectar Biosciences
High-Grade Glioma
1 trial -
CLR 131
Cellectar Biosciences
Pediatric Solid Tumor
1 trial -
I-131-CLR1404
Cellectar Biosciences
Cancer
1 trial -
I-131-CLR1404
Cellectar Biosciences
Multiple Myeloma
1 trial -
I-131-CLR1404
Cellectar Biosciences
Solid Tumors
1 trial -
I124-NM404
Cellectar Biosciences
Non Small Cell Lung Cancer
1 trial -
Iopofosine I 131
Cellectar Biosciences
Breast Cancer
1 trial
Frequently asked questions
How many clinical projects does Cellectar Biosciences have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.